Innocoll jumps on Phase III data for analgesic implant

Innocoll AG (NASDAQ:INNL) gained $3.40 (48%) to $10.51 after its XaraColl bupivacaine collagen sponge met the primary endpoint in the Phase III MATRIX-1 and MATRIX-2 studies to treat postoperative pain. The company plans to submit an NDA to FDA this year for the bioresorbable implant.

Innocoll said XaraColl improved the sum of pain intensity following hernia repair over 24 hours compared with placebo in MATRIX-1 (p=0.0004) and MATRIX-2 (p<0.0001), meeting both trials' primary endpoint. XaraColl also significantly reduced opioid consumption in the post-operative patients, a secondary endpoint. ...